- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| Do | BTIG upgrades Orchestra BioMed stock rating on trial progress | 1 | Investing.com | ||
| Do | BTIG stuft Orchestra BioMed Aktie hoch: Fortschritte bei klinischer Studie überzeugen | 2 | Investing.com Deutsch | ||
| 08.09. | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 19.08. | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | 1.105 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| 10.08. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates | 219 | GlobeNewswire (Europe) | The BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary... ► Artikel lesen | |
| 10.08. | Orchestra BioMed Holdings, Inc. Q2 Sales Decline | 1 | RTTNews | ||
| 29.06. | Aufnahme in Russell Indizes treibt Aktie von Orchestra BioMed an | 2 | Investing.com Deutsch | ||
| 29.06. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Joins Russell 3000 and Russell 2000 Indexes | 266 | GlobeNewswire (Europe) | NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to... ► Artikel lesen | |
| 23.06. | Orchestra BioMed Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 02.06. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 13.05. | Orchestra BioMed targets completed BACKBEAT enrollment by end of Q3 2026 | 8 | MassDevice | ||
| 12.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates | 561 | GlobeNewswire (Europe) | Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking... ► Artikel lesen | |
| 12.05. | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.05. | Orchestra BioMed targets Q3 2026 enrollment for hypertension trial | 3 | Investing.com | ||
| 12.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027 | 317 | GlobeNewswire (Europe) | Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026 Orchestra BioMed and Medtronic plc. (NYSE: MDT, "Medtronic"), the Company's... ► Artikel lesen | |
| 06.05. | Orchestra Biomed picks up $35M from Medtronic, Ligand | 15 | MassDevice | ||
| 06.05. | Medtronic investiert 20 Millionen US-Dollar in Orchestra BioMed | 43 | Investing.com Deutsch | ||
| 06.05. | Orchestra BioMed receives $15 million from Ligand financing deal | 1 | Investing.com | ||
| 06.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement | 527 | GlobeNewswire (Europe) | $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty... ► Artikel lesen | |
| 30.04. | Orchestra BioMed wins FDA breakthrough nod for pacemaker in hypertension | - | MassDevice |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| COGENT BIOSCIENCES | 33,410 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 16,160 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| IMMUNOVANT | 37,660 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 79,95 | 0,00 % | Jefferies erhöht Kursziel für Tarsus Pharmaceuticals nach Prognoseanhebung | ||
| SUMMIT THERAPEUTICS | 18,420 | 0,00 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| TYRA BIOSCIENCES | 25,070 | 0,00 % | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib | TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC
Favorable safety and tolerability results support chronic... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,530 | 0,00 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,405 | -0,15 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 24,265 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 33,640 | 0,00 % | Amylyx Pharmaceuticals, Inc. - 8-K, Current Report | ||
| ABSCI | 8,090 | 0,00 % | Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic | ||
| PRAXIS PRECISION MEDICINES | 330,41 | -0,04 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,060 | 0,00 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| VERA THERAPEUTICS | 34,040 | -0,03 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen | |
| ALUMIS | 9,190 | -0,33 % | Alumis Aktie steigt: Starke Studiendaten und Insiderkäufe beflügeln den Kurs |
ORCHESTRA BIOMED HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 5,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.